Clinuvel Pharmaceuticals

Candlestick Daily volume index Bar reversal Edit

Backtest results

Position Trades Duration Win rate Win/loss Avg win Avg loss Return
Long 10 4.5 20% 25% 1.6% -0.8% -3.4%
Short 5 4.2 40% 67% 1.9% -3.2% -5.9%

What indicators would you like to backtest?

Company

Indicator

Code Company Date Close Change Indicator Value Signal

Trading Performance

Fibonacci Retracements

Score

-1.05

Position Trades Duration Win Rate Win/Loss Avg Win Avg Loss Return
LONG 3 196.3 1.00% % 48.5% % 145.5%
SHORT 4 47.8 0.00% 0.00% 0.0% -12.6% -50.4%

Summary

Technical Analysis

Clinuvel Pharmaceuticals (CUV.AX)


Indicator:

FIBONACCI RETRACTION


Signal Strength: MEDIUM
Recommendation:

Indicator can be used in isolation or in additional to another technical indicator to confirmation for trading position.


Clinuvel Pharmaceuticals (ASX:CUV) : The current Fibonacci Retraction levels are:
(23.61%) $26.88
(38.2%) $28.36
(50%) $29.55
(61.8%) $30.74

The current support levels are:
(78.6%) $32.44
(100%) $34.6
(138.2%) $38.46
(161.8%) $40.84
(261.8%) $50.94
(423.61%) $67.28



A Fibonacci retracement is a term used in technical analysis that refers to areas of support (price stops going lower) or resistance (price stops going higher). Fibonacci retracement levels use horizontal lines to indicate areas of support or resistance at the key Fibonacci levels before the trend continues in the original direction.

Calculation: Fibonacci Retracements:
1) Uptrend: C = B — (B — A) x N%;
2) Downtrend: C = B + (A — B) x N%;
3) Fibonacci Levels:
a) 23.61%;
b) 38.2%;
c) 50%;
d) 61.8%;
e) 78.6%;
f) 100%,


PROFILE: Clinuvel Pharmaceuticals (CUV.AX)


Stock Exchange: ASX
Company: Clinuvel Pharmaceuticals
Ticker Codes: | CUV.AX | ASX:CUV |

About Clinuvel Pharmaceuticals (ASX:CUV):

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing drugs for the treatment of a range of severe skin disorders. Its lead drug compound is SCENESSE, a medicinal photoprotective and repigmentation drug that has completed Phase II and III trials in the United States and Europe, which is used for the prevention of phototoxicity in adults with erythropoietic protoporphyria. The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue that acts as a potent skin protectant; and VLRX001, an addition to the family of melanocortin analogues, which provoke increased and prolonged cellular activity. It has operations in Europe, the United States, and Singapore. The company is headquartered in Melbourne, Australia.

Top 10:

Fibonacci Retracements

Download
Company Close Change(%) Volume Value Signal
EPW ERM Power 2.45 42.4 11,431,310 0.25 BULLISH
VOC Vocus Communications 3.2 9.6 4,642,431 2.46 BULLISH
OML Ooh!Media 2.93 9.3 2,328,774 0.59 BULLISH
SDF Steadfast 3.81 7 5,307,131 0.49 BULLISH
WTC Wisetech Global 32.89 6.9 2,316,433 0.78 BULLISH
ISD Isentia 0.31 6.9 1,682,473 0.24 BULLISH
MCY Mighty River Power 5.05 6.8 10,062 0.45 BULLISH
URF Us Masters Residential Property Fund 0.8 6.7 48,505 1.76 BULLISH
CCL Coca-Cola Amatil 11.05 5.8 4,563,232 0.08 BULLISH
CDD Cardno 0.96 5.5 177,614 0.39 BULLISH